Benefits of cladribine tablets on the proportion of patients with multiple sclerosis free from clinical and radiological indicators of disease activity in the CLARITY EXTENSION study

被引：0
|
作者：
Giovannoni, G. [1 ]
Comi, G. [2 ,3 ]
Cook, S. [4 ]
Rieckmann, P. [5 ]
Rammohan, K. [6 ]
Soelberg-Sorensen, P. [7 ]
Vermersch, P. [8 ]
Adeniji, A. [9 ]
Dangond, F. [9 ]
机构：
[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[2] Univ Vita Salute San Raffaele, Osped San Raffaele, Dept Neurol, Milan, Italy
[3] Univ Vita Salute San Raffaele, Osped San Raffaele, Inst Expt Neurol, Milan, Italy
[4] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07102 USA
[5] Akad Krankenhaus Sozialstiftung, Neurol Klin, Bamberg, Germany
[6] Ohio State Univ Hosp, Columbus, OH 43210 USA
[7] Copenhagen Univ Hosp, Dept Neurol, Danish MS Ctr, Copenhagen, Denmark
[8] Univ Lille, CHU Lille, LIRIC, INSERM,U 995, Lille, France
[9] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
基金：
英国医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P636
引用
收藏
页码：300 / 301
页数：2
相关论文
共 50 条
  • [41] Efficacy of cladribine tablets 3.5mg/kg in patients with relapsing multiple sclerosis aged above and below 45 years; CLARITY and CLARITY Extension
    Giovannoni, G.
    Rammohan, K.
    Cook, S.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Keller, B.
    Di Cantogno, E. Verdun
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 492 - 492
  • [42] Selective and discontinuous reduction of B and T lymphocytes by cladribine tablets in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)
    Stuve, Olaf
    Soelberg-Sorensen, Per
    Giovannoni, Gavin
    Leist, Thomas
    Hyvert, Yann
    Damian, Doris
    Boschert, Ursula
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP11 - NP11
  • [43] Selective and discontinuous reduction of B and T lymphocytes by cladribine tablets in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)
    Stuve, O.
    Soelberg-Sorensen, P.
    Giovannoni, G.
    Leist, T.
    Hyvert, Y.
    Damian, D.
    Boschert, U.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 413 - 414
  • [44] Safety and Efficacy of Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis in Patients with High Disease Activity: Results from the Phase III, 96-Week CLARITY Study
    Rammohan, Kottil
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Kurukulasuriya, Nuwan C.
    Chang, Peter
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A612 - A613
  • [45] Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension
    Soelberg-Sorensen, P.
    Dangond, F.
    Hicking, C.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 598 - 599
  • [46] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
    Soelberg-Sorensen, Per
    Dangond, Fernando
    Hicking, Christine
    Giovannoni, Gavin
    NEUROLOGY, 2017, 88
  • [47] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
    Soelberg-Sorensen, Per
    Dangond, Fernando
    Hicking, Christine
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP12 - NP12
  • [48] Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis
    Galetta, Steven
    Calabresi, Peter
    Confavreux, Christian
    Giovannoni, Gavin
    Havrdova, Eva
    Hutchinson, Michael
    Kappos, Ludwig
    Lublin, Fred
    Miller, David
    O'Connor, Paul W.
    Phillips, J.
    Polman, Chris
    Radue, Ernst-Wilhelm
    Rudick, Richard
    Stuart, William
    Wojgt, Andrzej
    Weinstock-Guttman, Bianca
    Wynn, Daniel
    Pace, Amy
    Hyde, Robert
    Kim, Richard
    Panzara, Michael
    NEUROLOGY, 2008, 70 (11) : A89 - A90
  • [49] Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 305 - 306
  • [50] Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results fro the 120-Week Phase IIIb Extension Trial to the CLARITY Study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    NEUROLOGY, 2016, 86
12345